Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Explantation of durable ventricular assist device for myocardial functional recovery in children: A report from the ACTION registry.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
Same author

Successful thrombectomy for acute ischaemic stroke in an infant supported with a single ventricle assist device.

Cardiology in the young·2026
Same author

Key performance indicators for acute kidney replacement therapy in critically ill children: a systematic review.

Pediatric nephrology (Berlin, Germany)·2026
Same author

Prospective Multicenter Evaluation of a Novel Active Driving System for Pediatric Ventricular Assist Device Support.

Journal of the American College of Cardiology·2026
Same author

Double bridge to heart transplantation: Outcomes of early versus delayed extracorporeal membrane oxygenation crossover in pediatric population.

JTCVS open·2026
Same author

Impaired Oxygen Delivery Risk Analytics in the 6 Hours Before Extracorporeal Membrane Oxygenation: Single-Center Retrospective Cohort Study in Infants, 2013-2017.

Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies·2026

Related Experiment Video

Updated: Jul 26, 2026

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

9.3K

Multicenter outcomes for ventricular assist device support for failed stage II palliation.

Edon J Rabinowitz1,2, Mary Mehegan2, Anna Joong3

  • 1Division of Pediatric Critical Care Medicine, Washington University in St Louis, St Louis, Missouri.

JHLT Open
|March 27, 2025
PubMed
Summary

Systemic ventricular assist device (SVAD) use in failed stage II palliation (S2P) shows promising survival rates despite frequent complications. Further research is needed to optimize SVAD strategies for these complex pediatric patients.

Keywords:
Glennpediatricssingle ventriclestage 2 palliationtransplantationventricular assist device

More Related Videos

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.2K
Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
07:41

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

1.8K

Related Experiment Videos

Last Updated: Jul 26, 2026

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

9.3K
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.2K
Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
07:41

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

1.8K

Area of Science:

  • Pediatric Cardiology
  • Mechanical Circulatory Support
  • Congenital Heart Disease

Background:

  • Stage II palliation (S2P) is a complex surgical procedure for single ventricle physiology.
  • Failure of S2P often necessitates advanced interventions like ventricular assist devices (VADs).
  • Limited data exists on the outcomes of VAD use in patients with failed S2P.

Purpose of the Study:

  • To evaluate the clinical course, complications, and survival of systemic VADs (SVADs) in patients after failed S2P.
  • To identify factors associated with adverse events and mortality in this population.

Main Methods:

  • Multicenter retrospective review of the Advanced Cardiac Therapies Improving Outcomes Network registry.
  • Analysis of data from 34 patients implanted with SVADs between 2012 and 2022.
  • Assessment of preimplant characteristics, device strategies, adverse events, and survival outcomes.

Main Results:

  • The study identified 34 patients with a median age of 1.8 years requiring SVAD support post-S2P.
  • Frequent adverse events included infection (47%), strokes (29%), and bleeding (26%).
  • Survival to transplant or recovery was 76%, with 56% survival at 1-year postexplant.

Conclusions:

  • SVAD support demonstrates encouraging clinical outcomes in failed S2P, despite high rates of adverse events.
  • Center variability in device strategy exists, highlighting the need for further research.
  • Multi-institutional collaboration is crucial for optimizing SVAD support strategies in this patient group.